Unicycive Therapeutics (UNCY) Invested Capital (2020 - 2024)
Unicycive Therapeutics' (UNCY) quarterly Invested Capital came in at $208000.0 in Q1 2024, up 101.94% on a QoQ basis from $103000.0 in Q3 2021.
Unicycive Therapeutics (UNCY) Invested Capital (2020 - 2024) Analysis & Trends
Unicycive Therapeutics (UNCY) has 3 years of Invested Capital data on file, last reported at $208000.0 in Q1 2024.
- Quarterly Invested Capital changed N/A year-over-year to $208000.0 in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $208000.0 (changed N/A YoY) and the FY2020 annual result came in at $967000.0, changed N/A from the prior year.
- Invested Capital advanced to $208000.0 in Q1 2024, from $103000.0 in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $967000.0 in Q4 2020 to a low of $103000.0 in Q3 2021.
- A 3-year average of $544750.0 and a median of $554500.0 in 2021 frame the typical range for Invested Capital.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 190.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.45 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 380.00 Mn |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 208,000.00 |
| Sep 30, 2021 | 103,000.00 |
| Jun 30, 2021 | 901,000.00 |
| Dec 31, 2020 | 967,000.00 |